Received Mar 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z011862 | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z010437 | OT |
No additional AE; Caller reported AE on behalf of a patient who was inadvertently administered PROQUAD and VARIVAX concomitantly on 03/03/2026. Caller reported that they patient was expecting to receive 1 dose of VARIVAX and 1 dose of MMR-II.; Caller reported AE on behalf of a patient who was inadvertently administered PROQUAD and VARIVAX concomitantly on 03/03/2026. Caller reported that they patient was expecting to receive 1 dose of VARIVAX and 1 dose of MMR-II.; This spontaneous report was received from a physician assistant (reported as medical assistant) and refers to a 13-month-old male patient. The patient's concurrent conditions included fever, and illness (unspecified). Concomitant medications included hepatitis a vaccine inact (HAVRIX) and two topical creams (unspecified).The patient's medical history was not reported, previous drugs reactions and allergies were not reported. On 03-Mar-2026, it was stated that the patient was expecting to receive a dose of varicella virus vaccine live (oka-merck) (VARIVAX) and a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live lyophilisate and solvent for solution for injection (M-M-R II; however, he was inadvertently administered with a dose of varicella virus vaccine live (oka-merck) (VARIVAX) at a dose of 0.5 milliliters (mL) administered subcutaneously as prophylaxis (Lot No. Z010437 has been verified to be a valid lot number for [varicella virus vaccine live (oka-merck)], expiration date reported as 18-Jul-2027, but upon internal validation established as 18-Jun-2027) (anatomical location of administration and vaccination scheme frequency were not provided) and with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA [recombinant Human albumin]) (PROQUAD) at a dose of 0.5 milliliters (mL) administered subcutaneously as prophylaxis (Lot No. Z011862 has been verified to be a valid lot number for [measles, mumps, rubella and varicella (oka-merck) virus vaccine live], expiration date reported and upon internal validation established as 13-Jan-2027) (anatomical location of administration and vaccination scheme frequency were not provided); both reconstituted with sterile diluent, administered subcutaneously (Lot No., expiration date and indication were not provided) (accidental overdose) (wrong product administered). No additional adverse event was reported (no adverse event).
Fever; Illness
HAVRIX; Sterile diluent